Vaccines and antivirals for filoviruses

Biology and Pathogenesis of Rhabdo- and Filoviruses

Volumn , Issue , 2014, Pages 587-620

  Mire, Chad E ^a   Geisbert, Thomas W ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84988628611     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1142/9789814635349_0022     Document Type: Chapter

References (102)

1. Feldmann, H., Sanchez, A., Geisbert, T.W. (ed.) Filoviridae: Ebola and Marburg Viruses, Edn. 6th. (Lippincott Williams and Wilkins, Philadelphia; 2013).
2. Volchkova, V.A., Feldmann, H., Klenk, H.D. & Volchkov, V.E. The nonstructural small glycoprotein sGP of Ebola virus is secreted as an antiparallel-orientated homodimer. Virology 250, 408-414 (1998).
3. Mehedi, M. et al. A new Ebola virus nonstructural glycoprotein expressed through RNA editing. J Virol 85, 5406-5414 (2011).
4. Bukreyev, A.A. et al. Discussions and decisions of the 2012-2014 International Committee on Taxonomy of Viruses (ICTV) Filoviridae Study Group, January 2012-June 2013. Arch Virol (2013).
5. Kuhn, J.H. et al. Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviations. Arch Virol 155, 2083-2103 (2010).
6. Le Guenno, B. et al. Isolation and partial characterisation of a new strain of Ebola virus. Lancet 345, 1271-1274 (1995).
7. Barrette, R.W. et al. Discovery of swine as a host for the Reston ebolavirus. Science325, 204-206 (2009).
8. Hartman, A.L., Towner, J.S. & Nichol, S.T. Ebola and marburg hemorrhagic fever. Clin Lab Med 30, 161-177 (2010).
9. Outbreak news. Ebola haemorrhagic fever, Uganda. Wkly Epidemiol Rec 87, 339 (2012).
10. Outbreak news. Ebola haemorrhagic fever, Democratic Republic of the Congo. Wkly Epidemiol Rec 87, 338-339 (2012).
11. Baize, S. et al. Emergence of Zaire Ebola Virus Disease in Guinea - Preliminary Report. N Engl J Med (2014).
12. Outbreak news. Marburg haemorrhagic fever, Uganda. Wkly Epidemiol Rec 87, 437-438 (2012).
13. Bray, M., Davis, K., Geisbert, T., Schmaljohn, C. & Huggins, J. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis 178, 651-661 (1998).
14. Bray, M., Hatfill, S., Hensley, L. & Huggins, J.W. Haematological, biochemical and coagulation changes in mice, guinea-pigs and monkeys infected with a mouseadapted variant of Ebola Zaire virus. J Comp Pathol 125, 243-253 (2001).
15. Connolly, B.M. et al. Pathogenesis of experimental Ebola virus infection in guinea pigs. J Infect Dis 179 Suppl 1, S203-217 (1999).
16. Ebihara, H. et al. A Syrian golden hamster model recapitulating ebola hemorrhagic fever. J Infect Dis 207, 306-318 (2013).
17. Geisbert, T.W. et al. Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg Infect Dis 8, 503-507 (2002).
18. Ryabchikova, E. et al. Ebola virus infection in guinea pigs: presumable role of granulomatous inflammation in pathogenesis. Arch Virol 141, 909-921 (1996).
19. Warfield, K.L. et al. Development and characterization of a mouse model for Marburg hemorrhagic fever. J Virol 83, 6404-6415 (2009).
20. Baize, S. et al. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat Med 5, 423-426 (1999).
21. Geisbert, T.W. et al. Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses. Lab Invest 80, 171-186 (2000).
22. Bradfute, S.B. et al. Lymphocyte death in a mouse model of Ebola virus infection. J Infect Dis 196 Suppl 2, S296-304 (2007).
23. Swenson, D.L. et al. Monovalent virus-like particle vaccine protects guinea pigs and nonhuman primates against infection with multiple Marburg viruses. Expert Rev Vaccines7, 417-429 (2008).
24. Hevey, M., Negley, D., Pushko, P., Smith, J. & Schmaljohn, A. Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. Virology 251, 28-37 (1998).
25. Hevey M, N.D., Staley A, Schmaljohn A Determination of vaccine components required for protecting cynomolgus macaques against genotypically divergent isolates of Marburg virus. 20th Annual meeting of the American Society for Virology, Madison, Wisconsin, USA, W36-34 (2001).
26. Riemenschneider, J. et al. Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus. Vaccine 21, 4071-4080 (2003).
27. Geisbert, T.W. et al. Vector choice determines immunogenicity and potency of genetic vaccines against Angola Marburg virus in nonhuman primates. J Virol 84, 10386-10394 (2010).
28. Swenson, D.L. et al. Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections. Clin Vaccine Immunol 15, 460-467 (2008).
29. Jones, S.M. et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 11, 786-790 (2005).
30. Daddario-DiCaprio, K.M. et al. Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine. J Virol 80, 9659-9666 (2006).
31. Geisbert, T.W. et al. Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine 26, 6894-6900 (2008).
32. Geisbert, T.W. et al. Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus. J Virol 83, 7296-7304 (2009).
33. Warfield, K.L. et al. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J Infect Dis 196 Suppl 2, S430-437 (2007).
34. Herbert, A.S. et al. Venezuelan equine encephalitis virus replicon particle vaccine protects nonhuman primates from intramuscular and aerosol challenge with ebolavirus. J Virol 87, 4952-4964 (2013).
35. Sullivan, N.J., Sanchez, A., Rollin, P.E., Yang, Z.Y. & Nabel, G.J. Development of a preventive vaccine for Ebola virus infection in primates. Nature 408, 605-609 (2000).
36. Hensley, L.E. et al. Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species. PLoS Pathog 6, e1000904 (2010).
37. Sullivan, N.J. et al. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 424, 681-684 (2003).
38. Sullivan, N.J. et al. Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med 3, e177 (2006).
39. Pratt, W.D. et al. Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector. Clin Vaccine Immunol 17, 572-581 (2010).
40. Richardson, J.S., Pillet, S., Bello, A.J. & Kobinger, G.P. Airway delivery of an adenovirus-based ebola virus vaccine bypasses existing immunity to homologous adenovirus in nonhuman primates. J Virol 87, 3668-3677 (2013).
41. Geisbert, T.W. et al. Recombinant Adenovirus Serotype 26 (Ad26) and Ad35 Vaccine Vectors Bypass Immunity to Ad5 and Protect Nonhuman Primates against Ebolavirus Challenge. J Virol 85, 4222-4233 (2011).
42. Bukreyev, A. et al. Successful topical respiratory tract immunization of primates against Ebola virus. J Virol 81, 6379-6388 (2007).
43. Blaney, J.E. et al. Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine. PLoS Pathog 9, e1003389 (2013).
44. Qiu, X. et al. Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses. PLoS ONE 4, e5547 (2009).
45. Falzarano, D. et al. Single immunization with a monovalent vesicular stomatitis virus-based vaccine protects nonhuman primates against heterologous challenge with Bundibugyo ebolavirus. J Infect Dis 204 Suppl 3, S1082-1089 (2011).
46. Mire, C.E. et al. Vesicular stomatitis virus-based vaccines protect nonhuman primates against Bundibugyo ebolavirus. PLoS Negl Trop Dis 7, e2600 (2013).
47. Jasenosky, L.D., Neumann, G., Lukashevich, I. & Kawaoka, Y. Ebola virus VP40- induced particle formation and association with the lipid bilayer. J Virol 75, 5205-5214 (2001).
48. Licata, J.M., Johnson, R.F., Han, Z. & Harty, R.N. Contribution of ebola virus glycoprotein, nucleoprotein, and VP24 to budding of VP40 virus-like particles. J Virol 78, 7344-7351 (2004).
49. Hevey, M. et al. Marburg virus vaccines: comparing classical and new approaches. Vaccine 20, 586-593 (2001).
50. Lehrman, S. Virus treatment questioned after gene therapy death. Nature 401, 517-518 (1999).
51. Hitt, M.M. & Gauldie, J. Gene vectors for cytokine expression in vivo. Curr Pharm Des 6, 613-632 (2000).
52. Durbin, A.P. et al. Human parainfluenza virus type 3 (PIV3) expressing the hemagglutinin protein of measles virus provides a potential method for immunization against measles virus and PIV3 in early infancy. J Virol 74, 6821-6831 (2000).
53. Karron, R.A. et al. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants. Pediatr Infect Dis J 22, 394-405 (2003).
54. Bukreyev, A.A., Dinapoli, J.M., Yang, L., Murphy, B.R. & Collins, P.L. Mucosal parainfluenza virus-vectored vaccine against Ebola virus replicates in the respiratory tract of vector-immune monkeys and is immunogenic. Virology 399, 290-298 (2010).
55. Papaneri, A.B. et al. A replication-deficient rabies virus vaccine expressing Ebola virus glycoprotein is highly attenuated for neurovirulence. Virology 434, 18-26 (2012).
56. Roberts, A., Buonocore, L., Price, R., Forman, J. & Rose, J.K. Attenuated vesicular stomatitis viruses as vaccine vectors. J Virol 73, 3723-3732 (1999).
57. Rose, N.F. et al. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 106, 539-549 (2001).
58. Rose, N.F., Roberts, A., Buonocore, L. & Rose, J.K. Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1. J Virol 74, 10903-10910 (2000).
59. Fehr, T. et al. T-independent activation of B cells by vesicular stomatitis virus: no evidence for the need of a second signal. Cell Immunol 168, 184-192 (1996).
60. Zinkernagel, R.M., Adler, B. & Holland, J.J. Cell-mediated immunity to vesicular stomatitis virus infections in mice. Exp Cell Biol 46, 53-70 (1978).
61. Zinkernagel, R.M., Althage, A. & Holland, J. Target antigens for H-2-restricted vesicular stomatitis virus-specific cytotoxic T cells. J Immunol 121, 744-748 (1978).
62. Gaidamovich, S., Uvarov, V.N. & Alekseeva, A.A. [Isolation of vesicular stomatitis virus from a patient]. Vopr Virusol 11, 77-80 (1966).
63. Quiroz, E., Moreno, N., Peralta, P.H. & Tesh, R.B. A human case of encephalitis associated with vesicular stomatitis virus (Indiana serotype) infection. Am J Trop Med Hyg 39, 312-314 (1988).
64. Reif, J.S. et al. Epizootic vesicular stomatitis in Colorado, 1982: infection in occupational risk groups. Am J Trop Med Hyg 36, 177-182 (1987).
65. Mire, C.E. et al. Durability of a vesicular stomatitis virus-based marburg virus vaccine in nonhuman primates. PLoS ONE 9, e94355 (2014).
66. Marzi, A. et al. Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc Natl Acad Sci USA110, 1893-1898 (2013).
67. Johnson, J.E. et al. Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primates. Virology 360, 36-49 (2007).
68. Geisbert, T.W. et al. Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog 4, e1000225 (2008).
69. Hanson, R.P. The natural history of vesicular stomatitis. Bacteriol Rev 16, 179-204 (1952).
70. Jones, S.M. et al. Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever. J Infect Dis 196 Suppl 2, S404-412 (2007).
71. Mire, C.E. et al. Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates. PLoS Negl Trop Dis 6, e1567 (2012).
72. Geisbert, T.W. et al. Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet 362, 1953-1958 (2003).
73. Geisbert, T.W. et al. Marburg virus Angola infection of rhesus macaques: pathogenesis and treatment with recombinant nematode anticoagulant protein c2. J Infect Dis 196 Suppl 2, S372-381 (2007).
74. Hensley, L.E. et al. Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever. J Infect Dis 196 Suppl 2, S390-399 (2007).
75. Daddario-DiCaprio, K.M. et al. Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in nonhuman primates: an efficacy assessment. Lancet 367, 1399-1404 (2006).
76. Geisbert, T.W. et al. Postexposure treatment of Marburg virus infection. Emerg Infect Dis 16, 1119-1122 (2010).
77. Feldmann, H. et al. Effective post-exposure treatment of Ebola infection. PLoS Pathog 3, e2 (2007).
78. Geisbert, T.W. et al. Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. J Virol 82, 5664-5668 (2008).
79. Warren, T.K. et al. Advanced antisense therapies for postexposure protection against lethal filovirus infections. Nat Med 16, 991-994 (2010).
80. Geisbert, T.W. et al. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet 375, 1896-1905 (2010).
81. MacLachlan, I. et al. Development of lipid nanoparticle RNAi therapeutics against Ebola and Marburg hemorrhagic fever viruses. 6th International Symposium on Filoviruses (2014).
82. Dye, J.M. et al. Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc Natl Acad Sci USA 109, 5034-5039 (2012).
83. Qiu, X. et al. Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies. Sci Transl Med 4, 138ra181 (2012).
84. Qiu, X. et al. mAbs and Ad-Vectored IFN-alpha therapy rescue ebola-infected nonhuman primates when administered after the detection of viremia and symptoms. Sci Transl Med 5, 207ra143 (2013).
85. Olinger, G.G., Jr. et al. Delayed treatment of Ebola virus infection with plantderived monoclonal antibodies provides protection in rhesus macaques. Proc Natl Acad Sci USA 109, 18030-18035 (2012).
86. Warren, T.K. et al. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature 508, 402-405 (2014).
87. Gunther, S. et al. Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany. J Infect Dis 204 Suppl 3, S785-790 (2011).
88. Lebleu, B. et al. Cell penetrating peptide conjugates of steric block oligonucleotides. Adv Drug Deliv Rev 60, 517-529 (2008).
89. Fire, A. et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391, 806-811 (1998).
90. Wilkins, C. et al. RNA interference is an antiviral defence mechanism in Caenorhabditis elegans. Nature 436, 1044-1047 (2005).
91. Geisbert, T.W. et al. Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference. J Infect Dis 193, 1650-1657 (2006).
92. Fowler, T. et al. Inhibition of Marburg virus protein expression and viral release by RNA interference. J Gen Virol 86, 1181-1188 (2005).
93. Ursic-Bedoya, R. et al. Protection against lethal Marburg virus infection mediated by lipid encapsulated small interfering RNA. J Infect Dis 209, 562-570 (2014).
94. Emond, R.T., Evans, B., Bowen, E.T. & Lloyd, G. A case of Ebola virus infection. Br Med J 2, 541-544 (1977).
95. Mupapa, K. et al. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. J Infect Dis 179 Suppl 1, S18-23 (1999).
96. Pettitt, J. et al. Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail. Sci Transl Med 5, 199ra113 (2013).
97. Volchkova, V.A., Dolnik, O., Martinez, M.J., Reynard, O. & Volchkov, V.E. Genomic RNA editing and its impact on Ebola virus adaptation during serial passages in cell culture and infection of guinea pigs. J Infect Dis 204 Suppl 3, S941-946 (2011).
98. Kugelman, J.R. et al. Ebola virus genome plasticity as a marker of its passaging history: a comparison of in vitro passaging to non-human primate infection. PLoS ONE 7, e50316 (2012).
99. Mohan, G.S., Li, W., Ye, L., Compans, R.W. & Yang, C. Antigenic subversion: a novel mechanism of host immune evasion by Ebola virus. PLoS Pathog 8, e1003065 (2012).
100. Geisbert Progress in the development of vaccines against Ebola and Marburg viruses. 11th ASM Biodefense and Emerging Diseases Research Meeting (2013).
101. Roberts, R. & McCune, S.K. Animal studies in the development of medical countermeasures. Clin Pharmacol Ther 83, 918-920 (2008).
102. Bausch, D.G., Sprecher, A.G., Jeffs, B. & Boumandouki, P. Treatment of Marburg and Ebola hemorrhagic fevers: a strategy for testing new drugs and vaccines under outbreak conditions. Antiviral Res 78, 150-161 (2008).